EN DE
STOCK COMPARISON

Integral Diagnostics vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how Integral Diagnostics (IDX) and Thermo Fisher Scientific (TMO) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Integral Diagnostics trades at A$2.18 versus a fair value of A$0.49 (-77%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).
Integral Diagnostics
IDX.AU · AUD · Health Care
-77%
upside to fair value
overvalued
PriceA$2.18
Fair ValueA$0.49
Quality31/100
Thermo Fisher Scientific
TMO · USD · Health Care
-48%
upside to fair value
overvalued
Price$594
Fair Value$308
Quality63/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Integral DiagnosticsThermo Fisher Scientific
Valuation
51.5×P/E (TTM)29.5×
0.71×P/S (TTM)4.41×
0.78×P/B3.74×
7.8×EV/EBITDA20.0×
PEG1.74×
3.5%Dividend yield0.3%
A$0.07Dividend per share$1.76
Profitability
2%Net margin15%
8%Operating margin18%
2%Return on equity14%
3%Return on assets5%
Growth
56%Revenue growth (YoY)6%
20.5%Avg. growth/yr (3Y)-0.3%
18.0%Avg. growth/yr (5Y)6.7%
Balance & size
0.49×Debt / equity0.67×
$543MMarket cap$199B
healthyGrowth qualityhealthy

Integral Diagnostics leads: 8 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Integral Diagnosticsof which business quality 34 · market factors 41 Thermo Fisher Scientificof which business quality 60 · market factors 65
ProfitabilityMargins and returns on capital today
31
43
Quality GrowthAre margins and returns improving?
71
31
CashflowEarnings quality: real cash, not paper profit
43
62
Fin. StrengthBalance sheet, leverage, solvency risk
35
60
InvestmentDisciplined investing over empire-building
19
79
Low VolatilityCalm price path (market factor)
84
68
MomentumPrice trend over the last 3–12 months (market factor)
24
58
52W MomentumDistance to the 52-week high (market factor)
20
72
Net IssuanceBuybacks instead of dilution
0
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Integral Diagnostics

DCF ModelsA$2.79
Earnings-BasedA$0.45
Dividend DiscountA$0.56
MultiplesA$0.76
Asset-BasedA$1.24
Growth DCFA$0.95
Economic ProfitA$0.78
Growth EarningsA$0.58

19 of 22 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Integral Diagnostics
Bear A$0.35Fair Value A$0.49Bull A$0.67
A$2.18 = current price (white tick)
Thermo Fisher Scientific
Bear $175Fair Value $308Bull $385
$594 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Integral Diagnostics · Health Care

Quality score31 · bottom 25%
Fair value upside-77% · bottom 25%

Thermo Fisher Scientific · Health Care

Quality score63 · above median
Fair value upside-48% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Integral Diagnostics trades at A$2.18 versus a fair value of A$0.49 (-77%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).

Thermo Fisher Scientific has the higher quality score (63/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.